drugset
drugset / Trial / NCT06037148

Study to Evaluate Safety, Tolerability and Explorative Efficacy of DM-101PX in Birch Pollen Allergic Participants

NCT06037148 ↗

Phase 1 Completed 30 enrolled Desentum Oy
RandomizedSequentialDouble-blindOther

Summary

Randomized, double-blind placebo-controlled phase I trial with the primary aim to investigate safety and tolerability of three ascending dosing schemes of DM-101-PX in birch pollen allergic adults. As an explorative objective, the trial will also investigate the effect of DM-101PX on the allergic symptoms following birch pollen allergen exposure in a chamber. Expanded access to the study treatment is not available.

Timeline

Start
2023-09-07
Primary completion
2024-03-06
Completion
2024-03-06

Drugs

EvaluationDrugModalityDoseRoute
Subject DM-101PX Unknown 0.05 ug Subcutaneous
Subject DM-101PX Unknown 0.1 ug Subcutaneous
Subject DM-101PX Unknown 0.2 ug Subcutaneous

Indications

No indication recorded.